Ad
related to: letairis specialty pharmacy
Search results
Results from the WOW.Com Content Network
Ambrisentan is a drug that blocks endothelin, an endogenous hormone found in higher quantities in patients with pulmonary arterial hypertension. Endothelin binds to two receptors, ET A and ET B . ET A is responsible for cell growth in the vessels as well as vasoconstriction , while ET B plays a role in vasodilation , endothelin 1 clearance, and ...
Volibris (ambrisentan) Wellbutrin (bupropion hydrochloride) Wellvone (atovaquone) Zantac (ranitidine hydrochloride) Zeffix (lamivudine) Zejula (niraparib) Zentel (albendazole) Zinacef (cefuroxime) Zinnat (cefuroxime axetil) Zovirax (aciclovir) Zyban (bupropion hydrochloride)
sitaxentan, ambrisentan, atrasentan, BQ-123, sparsentan, zibotentan, avosentan, edonentan, clazosentan; Selective ET B Receptor Antagonists, which affect endothelin B receptors. BQ-788 and A192621 are used in research but have not yet reached clinical trial stage
By 2001 CVS' specialty pharmacy ProCare was the "largest integrated retail/mail provider of specialty pharmacy services" in the United States. [18]: 10 It was consolidated with their pharmacy benefit management company, PharmaCare in 2002. In their 2001 annual report CVS anticipated that the "$16 billion specialty pharmacy market" would grow at ...
The top ten specialty pharmacies in 2014 were CVS Specialty parent company CVS Health with $20.5B in sales, Express Scripts's Accredo at $15B, Walgreens Boots Alliance's Walgreens Specialty at $8.5B, UnitedHealth Group's OptumRx at $2.4B, Diplomat Pharmacy at $2.1B, Catamaran's BriovaRx at $2.0B, Specialty Prime Therapeutics's Prime ...
In October 2014, Diplomat Pharmacy launched an initial public offering (IPO) on the New York Stock Exchange after raising $173 million. [6] Diplomat is the only publicly traded company in the United States that offers a specialty pharmacy independent of pharmacy benefit manager, health plan, retail chain, or wholesaler ownership. [7]
Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.Under normal conditions, endothelin-1 binding of ET-A receptors causes constriction of the pulmonary blood vessels. [8]
Macitentan blocks the ET1-dependent rise in intracellular calcium by inhibiting the binding of ET-1 to ET receptors. Blocking of the ETA receptor subtype seems to be of more importance in the treatment of PAH than blocking of ETB, likely because there are higher numbers of ETA receptors than ETB receptors in pulmonary arterial smooth muscle cells. [9]
Ad
related to: letairis specialty pharmacy